Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
Lasho
Terra L
TL
Mesa
Ruben
R
Gilliland
D Gary
DG
Tefferi
Ayalew
A
D018941:Antigens, CD19 / Q000032:analysis; D018952:Antigens, CD34 / Q000032:analysis; D001402:B-Lymphocytes / Q000201:enzymology; D015415:Biomarkers / Q000032:analysis; D017252:CD3 Complex / Q000032:analysis; D002454:Cell Differentiation; D049109:Cell Proliferation; D004252:DNA Mutational Analysis; D006098:Granulocytes / Q000201:enzymology*; D006720:Homozygote; D006801:Humans; D053614:Janus Kinase 2; D009196:Myeloproliferative Disorders / Q000201:enzymology / Q000235:genetics*; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D013601:T-Lymphocytes / Q000201:enzymology
D018941:Antigens, CD19; D018952:Antigens, CD34; D015415:Biomarkers; D017252:CD3 Complex; D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2